Spain represents one of the most exciting incoming additions to the European medical cannabis market this year, as one of the continent’s largest producers finally moves toward domestic patient access after years of hard-fought advocacy.
However, with a critical three-month deadline approaching to determine the clinical uses, dosage parameters, and prescription conditions of the incoming framework expires today, new legal challenges submitted to Spain’s Supreme Court could further delay its rollout.
While further delays will be difficult news for patients and advocacy groups who have been fighting tooth and nail for access to medical cannabis since 2022, the legal challenges from Spain’s community of pharmacies could dramatically improve access across the country.
Two separate appeals have now been filed by pharmacy associations just weeks apart, each challenging the Royal Decree’s stipulation that cannabis prescriptions can only be dispensed from Hospital Pharmacy services.
The General Council of Official Colleges of Pharmacists (Cgcof), representing Spain’s 22,000 community pharmacies, filed a ‘recurso contencioso-administrativo’ (contentious-administrative appeal) with the Supreme Court following notification in the Official State Gazette (BOE) on January 3rd.
The move came just weeks after the Andalusian Confederation of Pharmacy Offices (CEOFA) filed a similar challenge in mid-December, both targeting Royal Decree 903/2025 that was approved by the Council of Ministers in October.
The BOE notification invites ‘all natural and legal persons with a legitimate interest’ to appear and join the case as defendants within nine days of the announcement, opening the possibility for additional pharmacy organisations, patient advocacy groups, or other stakeholders to join either appeal.
Both appeals challenge the decree’s Article 8, which states that standardised cannabis preparations ‘may only be supplied to legally established Hospital Pharmacy services, or for export.’
Under the decree, these hospital pharmacy services are exclusively responsible for preparing cannabis-based “master formulas” from standardised preparations in response to medical prescriptions, and for dispensing them to both inpatients and outpatients.
The decree establishes Spain’s first comprehensive framework for cannabis-derived medicines, covering four specific indications: spasticity due to multiple sclerosis, severe refractory epilepsy, nausea and vomiting caused by chemotherapy, and chronic refractory pain. The framework explicitly excludes cannabis flower, limiting treatments to oils and other extract-based preparations.
Only specialist physicians working in hospital settings can prescribe the medications under the current framework, and patients will be added to a centralised registry managed by the Spanish Agency for Medicines and Health Products (AEMPS). The decree mandates that cannabis-based preparations can only be prescribed as a last resort, after patients have demonstrated that other authorised medications, such as Sativex, have proven ineffective.
The AEMPS was given three months from the decree’s October publication to issue clinical monographs detailing the specific authorised uses, dosage parameters, and prescription conditions, a deadline that arrived in early January, coinciding with the Cgcof’s Supreme Court filing.
According to the Ministry of Health, this approach will ‘allow for continuous updating based on scientific advances and available clinical evidence, paving the way for the incorporation of new indications in the future, always under rigorous criteria of efficacy, safety, and medical necessity.’
January 9, 2026 No Comments
October 8, 2025 No Comments
March 17, 2025 No Comments
Both appeals challenge the decree on multiple grounds, with a strong emphasis on patient access and equity rather than business interests.
CEOFA’s December appeal argues the decree ‘incurs in a regulatory excess, violating the principle of normative hierarchy and directly contradicting the provisions of the Law on Guarantees and Rational Use of Medicines and Health Products.’
The confederation contends that current legislation already recognises community pharmacies’ legal capacity to prepare compounded medications according to the National Formulary when they have the necessary resources.
The appeal argues that Article 8 ‘unduly limits an activity that the law does not restrict’ while ‘invading regional powers in matters of pharmaceutical regulation, such as the authorisation of facilities and formulation laboratories.’
CEOFA also contends the decree ‘usurps functions that belong to the AEMPS, an independent technical body to whom the law attributes the classification of medicines and the determination of its prescription and dispensing conditions.’
Central to both appeals is the question of patient access. “The network of community pharmacies guarantees accessibility, territorial equity, and close, professional pharmaceutical care, especially in rural areas or those with limited healthcare resources,” CEOFA stated in its appeal.
“Excluding them without a legal or technical basis represents an unnecessary obstacle to patients’ access to treatments that the Royal Decree itself recognises as potentially beneficial for serious illnesses.”
The Cgcof’s January appeal focuses on the lack of justification for the restriction. “There is no health, legal, or safety reason whatsoever that justifies limiting its dispensing exclusively to Hospital Pharmacy services, preventing the preparation of compounded medications and patients’ access to them through the network of community pharmacies,” the organisation stated.
Cgcof President Jesús Aguilar has emphasised that community pharmacies already routinely handle controlled medications, including opioids like fentanyl, under strict regulatory oversight, making the exclusion of cannabis preparations appear arbitrary.
Both appeals also point to internal contradictions within the decree itself. While Article 8 explicitly reserves cannabis preparation and dispensing for hospital pharmacies, Additional Provision Two and Article 9.3 acknowledge that autonomous communities may establish ‘non-face-to-face dispensing measures’ in cases of ‘vulnerability, dependency, or geographical remoteness.’
The Supreme Court’s Administrative Chamber will now review both challenges, though the timeline for a decision remains unclear. Spanish administrative law cases can take months or even years to resolve, particularly when they involve complex questions of regulatory authority and constitutional principles.
The nine-day window for additional parties to join the appeals is set to close this weekend, though it remains unclear whether any patient advocacy groups, industry stakeholders, or other pharmacy organisations will opt to join either challenge.
In the meantime, implementation of the medical cannabis framework continues. The AEMPS was required to publish clinical monographs detailing authorised uses, dosage parameters, and prescription conditions within three months of the decree’s October publication, a deadline that falls today (January 09, 2026). Whether the agency will proceed with publishing these monographs while the legal challenges are pending or await the Supreme Court’s decision remains to be seen.
The outcome of these appeals could significantly reshape Spain’s medical cannabis landscape. If successful, the challenges could force the Ministry of Health to revise the decree to include community pharmacies, potentially expanding access to thousands more patients, particularly in rural areas. However, such a revision would likely delay implementation further, extending the wait for patients who have been advocating for legal access since 2022.
The post Spanish Pharmacists Appeal Hospital-Only Cannabis Rule as Key Regulatory Deadline Passes Unmet appeared first on Business of Cannabis.
Continue reading...
However, with a critical three-month deadline approaching to determine the clinical uses, dosage parameters, and prescription conditions of the incoming framework expires today, new legal challenges submitted to Spain’s Supreme Court could further delay its rollout.
While further delays will be difficult news for patients and advocacy groups who have been fighting tooth and nail for access to medical cannabis since 2022, the legal challenges from Spain’s community of pharmacies could dramatically improve access across the country.
Two separate appeals have now been filed by pharmacy associations just weeks apart, each challenging the Royal Decree’s stipulation that cannabis prescriptions can only be dispensed from Hospital Pharmacy services.
What happened?
The General Council of Official Colleges of Pharmacists (Cgcof), representing Spain’s 22,000 community pharmacies, filed a ‘recurso contencioso-administrativo’ (contentious-administrative appeal) with the Supreme Court following notification in the Official State Gazette (BOE) on January 3rd.
The move came just weeks after the Andalusian Confederation of Pharmacy Offices (CEOFA) filed a similar challenge in mid-December, both targeting Royal Decree 903/2025 that was approved by the Council of Ministers in October.
The BOE notification invites ‘all natural and legal persons with a legitimate interest’ to appear and join the case as defendants within nine days of the announcement, opening the possibility for additional pharmacy organisations, patient advocacy groups, or other stakeholders to join either appeal.
Both appeals challenge the decree’s Article 8, which states that standardised cannabis preparations ‘may only be supplied to legally established Hospital Pharmacy services, or for export.’
Under the decree, these hospital pharmacy services are exclusively responsible for preparing cannabis-based “master formulas” from standardised preparations in response to medical prescriptions, and for dispensing them to both inpatients and outpatients.
The decree establishes Spain’s first comprehensive framework for cannabis-derived medicines, covering four specific indications: spasticity due to multiple sclerosis, severe refractory epilepsy, nausea and vomiting caused by chemotherapy, and chronic refractory pain. The framework explicitly excludes cannabis flower, limiting treatments to oils and other extract-based preparations.
Only specialist physicians working in hospital settings can prescribe the medications under the current framework, and patients will be added to a centralised registry managed by the Spanish Agency for Medicines and Health Products (AEMPS). The decree mandates that cannabis-based preparations can only be prescribed as a last resort, after patients have demonstrated that other authorised medications, such as Sativex, have proven ineffective.
The AEMPS was given three months from the decree’s October publication to issue clinical monographs detailing the specific authorised uses, dosage parameters, and prescription conditions, a deadline that arrived in early January, coinciding with the Cgcof’s Supreme Court filing.
According to the Ministry of Health, this approach will ‘allow for continuous updating based on scientific advances and available clinical evidence, paving the way for the incorporation of new indications in the future, always under rigorous criteria of efficacy, safety, and medical necessity.’
Spanish Pharmacists Appeal Hospital-Only Cannabis Rule as Key Regulatory Deadline Passes Unmet
Read More »January 9, 2026 No Comments
Spain Becomes Latest European Medical Cannabis Market as First National Rules Given Green Light
Read More »October 8, 2025 No Comments
UK Has Imported More Cannabis From Spain than Any Other Country Since 2021, New Figures Show
Read More »March 17, 2025 No Comments
The Legal Arguments
Both appeals challenge the decree on multiple grounds, with a strong emphasis on patient access and equity rather than business interests.
CEOFA’s December appeal argues the decree ‘incurs in a regulatory excess, violating the principle of normative hierarchy and directly contradicting the provisions of the Law on Guarantees and Rational Use of Medicines and Health Products.’
The confederation contends that current legislation already recognises community pharmacies’ legal capacity to prepare compounded medications according to the National Formulary when they have the necessary resources.
The appeal argues that Article 8 ‘unduly limits an activity that the law does not restrict’ while ‘invading regional powers in matters of pharmaceutical regulation, such as the authorisation of facilities and formulation laboratories.’
CEOFA also contends the decree ‘usurps functions that belong to the AEMPS, an independent technical body to whom the law attributes the classification of medicines and the determination of its prescription and dispensing conditions.’
Central to both appeals is the question of patient access. “The network of community pharmacies guarantees accessibility, territorial equity, and close, professional pharmaceutical care, especially in rural areas or those with limited healthcare resources,” CEOFA stated in its appeal.
“Excluding them without a legal or technical basis represents an unnecessary obstacle to patients’ access to treatments that the Royal Decree itself recognises as potentially beneficial for serious illnesses.”
The Cgcof’s January appeal focuses on the lack of justification for the restriction. “There is no health, legal, or safety reason whatsoever that justifies limiting its dispensing exclusively to Hospital Pharmacy services, preventing the preparation of compounded medications and patients’ access to them through the network of community pharmacies,” the organisation stated.
Cgcof President Jesús Aguilar has emphasised that community pharmacies already routinely handle controlled medications, including opioids like fentanyl, under strict regulatory oversight, making the exclusion of cannabis preparations appear arbitrary.
Both appeals also point to internal contradictions within the decree itself. While Article 8 explicitly reserves cannabis preparation and dispensing for hospital pharmacies, Additional Provision Two and Article 9.3 acknowledge that autonomous communities may establish ‘non-face-to-face dispensing measures’ in cases of ‘vulnerability, dependency, or geographical remoteness.’
What happens next?
The Supreme Court’s Administrative Chamber will now review both challenges, though the timeline for a decision remains unclear. Spanish administrative law cases can take months or even years to resolve, particularly when they involve complex questions of regulatory authority and constitutional principles.
The nine-day window for additional parties to join the appeals is set to close this weekend, though it remains unclear whether any patient advocacy groups, industry stakeholders, or other pharmacy organisations will opt to join either challenge.
In the meantime, implementation of the medical cannabis framework continues. The AEMPS was required to publish clinical monographs detailing authorised uses, dosage parameters, and prescription conditions within three months of the decree’s October publication, a deadline that falls today (January 09, 2026). Whether the agency will proceed with publishing these monographs while the legal challenges are pending or await the Supreme Court’s decision remains to be seen.
The outcome of these appeals could significantly reshape Spain’s medical cannabis landscape. If successful, the challenges could force the Ministry of Health to revise the decree to include community pharmacies, potentially expanding access to thousands more patients, particularly in rural areas. However, such a revision would likely delay implementation further, extending the wait for patients who have been advocating for legal access since 2022.
The post Spanish Pharmacists Appeal Hospital-Only Cannabis Rule as Key Regulatory Deadline Passes Unmet appeared first on Business of Cannabis.
Continue reading...
